Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Clinical trial NCT06465953 · RECRUITING

Trial details

NCT number: NCT06465953
Sponsor: Institut de Recherches Internationales Servier
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)

Start date: 2024-12-03
Primary completion: 2027-11-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.